Vivos Therapeutics Q1 revenue jumps, driven by SCN acquisition

Vivos Therapeutics

20/05/2026 21:19

Overview

U.S. sleep disorder device maker's Q1 revenue rose 70% yr/yr, driven by SCN acquisition

Gross profit for Q1 increased 103% yr/yr, with gross margin rising to 60%

Q1 net loss doubled to $7.8 mln due to expansion and higher operating expenses

Outlook

Company expects continued integration and growth from SCN and medical provider collaborations

Vivos is working to secure funding and restructure debt to reduce cash burn

Company expects certain professional fees incurred in Q1 will not recur this yr

Result Drivers

SCN ACQUISITION - Revenue growth was driven by the acquisition of The Sleep Center of Nevada and related business model changes

SERVICE REVENUE MIX - Increase in sleep testing services and treatments at SCN locations boosted service revenue

LOWER CUSTOMER ACQUISITION COSTS - Company reported a significant reduction in customer acquisition costs following its business model pivot

Company press release: ID:nGNX2ZJblP

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$7.75 mln
Q1 Gross Profit
$3.06 mln
Q1 Operating Income
-$6.61 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Vivos Therapeutics Inc is $2.50, about 327.3% above its May 19 closing price of $0.59

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)